Fran Boyle
speaker
110 appearances
2 recordings
1 series
first heard Nov 2016
last heard Jun 2018
Fran Boyle’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
The high-risk group, yes, they benefit.
And usually you can work that out from other features of the cancer.
It's that younger group where chemotherapy probably has an additional hormone blocking effect.
And so if you've got a very hormonal cancer and you're younger, chemo doesn't just work killing cells directly.
It also knocks off cells in the ovary and that reduces the amount of estrogen around.
And so from lots of other trials that we've done, we know that that extra hormone blocking effect can be beneficial.
So it isn't clear at this point
what percentage of those younger women had their period stop.
And that would be good to know.
Well, she should definitely talk to her oncologist about the basis on which the decisions were made.
There are some other tests that are available in Australia that also categorise women in a similar way to lower or higher risk.
So the Oncotype DX, which was the 21 gene test, is not the only way to address this.
Some women will have had those tests, but they, like the Oncotype, are expensive.
So this is not
None of these tests are presently covered by Medicare.
much do they cost?
An Oncotype is about $4,500.
It is.
So
Well, not very many patients, in fact, because when the test is discussed with them, obviously that's a massive out-of-pocket expense at a time when they're having potentially other costs for surgery and the like.
Showing 41–60 of 110 · page 3 of 6
← Previous
Next →